All News
Predicting RA, and Treatment of Subclinical Arthritis
Identifying patients that will develop RA in situations of seropositivity without overt clinical arthritis or identifying patients with undifferentiated oligo/polyarthritis that will develop RA remains a challenge in the field of rheumatology.
Read Article
Psoriatic Arthritis: "What Matters" to Patients, Physicians
A study presented today by Mease et al. addresses the vital gap between what patients and physicians consider disabling because of PsA, and emphasizes “what matters” in a daily clinical encounter while dealing with PsA.
Read Article
Can "Ultra-low" dose Rituximab work for RA?
At day 3 of #ACR21, the REDO trial presented data in abs1443 in an oral presentation challenging how low we can go with rituximab for rheumatoid arthritis.
Dr. Eric Dein ( @ejdein1) shares highlights.
https://t.co/jaTjBPRKVe https://t.co/7Q9nxlUt7R
Links:
Dr. John Cush RheumNow ( View Tweet)
Psoriatic Arthritis: What's with Brepocitinib? Dr. Eric Ruderman ( @JointMD ) discusses abstract #0488 presented at the #ACR21 annual meeting.
https://t.co/mq0IMwyMSk https://t.co/oJAJS0DpQz
Links:
Dr. John Cush RheumNow ( View Tweet)
Lupus Day 2 Highlights: Drs Dao , Mehta, Yusof, Pope, Reyes and Castillo review lupus-related information and data presented during day 2 of the #ACR21 annual
meeting.
https://t.co/QX6Ay77FKo
@KDAO2011 @bella_mehta @Yuz6Yusof @Janetbirdope @RHEUMarampa @_Castillo_Pedro https://t.co/ldAHqXsi0G
Links:
Dr. John Cush RheumNow ( View Tweet)
RA: Cardiovascular Risk Stratification and Potential Predictors of Risk
Dr. El Ramahi ( @MeralElRamahiMD ) shares important takeaways from abstracts presented at #ACR21.
https://t.co/69E7aA0Wag https://t.co/6nR5TLeyga
Links:
Dr. John Cush RheumNow ( View Tweet)
Spondyloarthritis Roundtable Rehash of #ACR21
New therapies, delay in diagnosis, artificial intelligence in reading radiographs and MRIs, and more. Panelists includes Dr. Alexis Ogdie-Beatty, Dr. Jose Scher, Dr. Jack Cush and Dr. Christopher Ritchlin.
https://t.co/K0pbddzLAF https://t.co/fS6wBNWOdJ
Links:
Dr. John Cush RheumNow ( View Tweet)
Day 4 Report from #ACR21
My favorite three presentations from day 4 at ACR 2021 included the following:
-Breakthrough Infections in Rheumatic Disease Patients
-Secukinumab in Giant Cell Arteritis
-STOP-Gout – Febuxostat is Noninferior to Allopurinol
https://t.co/zJRS5AHjc1 https://t.co/FuwCFCK14r
Links:
Dr. John Cush RheumNow ( View Tweet)
Cognitive Impairment in Patients with Rheumatoid Arthritis
Dr. Akhil Sood ( @AkhilSoodMD) discusses abstracts presented at #ACR21.
https://t.co/zz8auqZjIW https://t.co/RSHjyonBrj
Links:
Dr. John Cush RheumNow ( View Tweet)
Predictors to Flare in SpA: Dr. Antoni Chan ( @synovialjoints ) discusses abstracts #0929 and #0916 presented at the #ACR21 annual meeting.
https://t.co/C0NLSTzlW9 https://t.co/3BiW2L6BJu
Links:
Dr. John Cush RheumNow ( View Tweet)
Can we Use Frax Score in RA Patients? Dr. Eric Dein ( @ejdein1) reviews abstract #0563 presented at the #ACR21 annual meeting.
https://t.co/UcvTWhlcvW https://t.co/8AdHa2enlz
Links:
Dr. John Cush RheumNow ( View Tweet)
An Exclusive Interview with Dr. Al Kim (#Wowkim): Dr. Kathryn Dao ( @KDAO2011 ) interviews Dr. Alfred Kim (aka #Wowkim) about the exciting work he's presenting at the #ACR21 annual meeting.
https://t.co/34EZIz2OFG https://t.co/mhaUcIhTKu
Links:
Dr. John Cush RheumNow ( View Tweet)
ACR21 Best Abstracts - Day 4
On the last day of #ACR21 Annual Meeting, the RheumNow faculty selected their favorite reports. Follow the link below for our selections!
https://t.co/O6IXf5iB3d https://t.co/G1yUzqwcuk
Links:
Dr. John Cush RheumNow ( View Tweet)
Predictors of Remission and Low Disease Activity in SLE
Dr. Sheila Reyes ( @RHEUMarampa) shares results of abstracts discussed at #ACR21.
https://t.co/FayzgyGiP8 https://t.co/QvKbKnznmS
Links:
Dr. John Cush RheumNow ( View Tweet)
Serum Biomarkers Distinguish Radiographic Progression in PsA: Dr. Robert Chao ( @doctorRBC ) discusses abstract #0449 presented at the #ACR21 annual meeting. https://t.co/Q9JQyx7K1A
Dr. John Cush RheumNow ( View Tweet)
Emapalumab for the treatment of macrophage activation syndrome
Dr. Yuz Yusof ( @Yuz6Yusof) summarizes abstracts presented at #ACR21.
https://t.co/TXdbwA64wg https://t.co/VLiLIsEkxS
Links:
Dr. John Cush RheumNow ( View Tweet)
Predictors of mortality in RA lung disease? Dr. Meral El Ramahi ( @MeralElRamahiMD) discusses abstract #0290 presented at the #ACR21 annual meeting.
https://t.co/swo0eexWHl https://t.co/dVpeTQIwTb
Links:
Dr. John Cush RheumNow ( View Tweet)
Depression in Axial Spondyloarthritis: Dr. Mrinalini Dey ( @DrMiniDey) discusses abstract #1305 presented at the #ACR21 annual meeting.
https://t.co/KUGM61fpZK https://t.co/YhyvGUJkO0
Links:
Dr. John Cush RheumNow ( View Tweet)
#ACR21 – Day 3 Report
Day 3 presentations were big! We share a few of our favorites.
https://t.co/UfWIFq2lWb https://t.co/Z8VKGXvPzz
Links:
Dr. John Cush RheumNow ( View Tweet)
Monitoring Infliximab Drug Levels Improves Efficacy
Should we start considering therapeutic drug monitoring when prescribing TNFi for treatment of our rheumatologic conditions?
Dr. Robert Chao ( @doctorRBC) shares data presented at #ACR21.
https://t.co/IJ9by2iguK https://t.co/KBIWTs9iPV
Links:
Dr. John Cush RheumNow ( View Tweet)